Home › Oligodendroglioma › New Jersey
Oligodendroglioma clinical trials in New Jersey
3 studies for Oligodendroglioma are looking for participants at sites in New Jersey.
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
- Cooper University HealthCare, Camden
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 9, 2026 · NCT07439172From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.